The medical community is excited with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 receptor that’s showing significant potential in clinical trials for addressing obesity. Unlike some current weight loss solutions, retatrutide appears to deliver a more substantial decrease in body mass and enhance metabolic function, part